As of Q4'25, Eli Lilly (LLY) reported revenue of USD 19.29B, marking the highest quarterly revenue in the period covered. Year-over-year revenue growth for this quarter reached 42.56%, reflecting a robust acceleration compared to previous quarters. From Q1'23 to Q4'25, LLY's revenue demonstrated a strong upward trend, rising from USD 6.96B to USD 19.29B. After a slight decline in Q1'23, the company experienced consistent growth, with notable surges in Q2'24 and Q3'25. Year-over-year growth rates remained positive throughout most of the period, peaking at 53.87% in Q3'25, indicating sustained momentum and significant expansion in recent quarters.